<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Ronald C. Petersen</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>220</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-0188-913X" target="_blank">0000-0002-0188-913X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Mild Cognitive Impairment](/diseases/mci), Biomarkers</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Amyloid, [Tau](/proteins/tau), Biomarkers, Clinical Trials</td>
</tr>
</table>
Ronald C. Petersen
Overview
Ronald C. Petersen plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Ronald C. Petersen</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>220</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-0188-913X" target="_blank">0000-0002-0188-913X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Mild Cognitive Impairment](/diseases/mci), Biomarkers</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Amyloid, [Tau](/proteins/tau), Biomarkers, Clinical Trials</td>
</tr>
</table>
Ronald C. Petersen
Overview
Ronald C. Petersen plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Recent Research
Recent PubMed-indexed publications (2024-present):
[Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohorts](https://pubmed.ncbi.nlm.nih.gov/39888585/). GeroScience. 2025.
[Age and early life adversity shape heterogeneity of the epigenome across tissues in macaques](https://pubmed.ncbi.nlm.nih.gov/40791500/). bioRxiv : the preprint server for biology. 2025.
[X-chromosome-wide association study for Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/39633006/). Molecular psychiatry. 2025.
[Glioblastoma therapy: State of the field and future prospects](https://pubmed.ncbi.nlm.nih.gov/39537100/). Life sciences. 2024.
[Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)](https://pubmed.ncbi.nlm.nih.gov/39636028/). Journal of Alzheimer's disease : JAD. 2024.
Career Background
Dr. Petersen completed his medical training and neurology residency at the Mayo Clinic, where he also pursued research training in cognitive neuroscience. He has served as the director of the Mayo Clinic Alzheimer's Disease Research Center for over two decades and has been a leading figure in defining the concept of mild cognitive impairment as a precursor to Alzheimer's disease.
Research Focus
Mild Cognitive Impairment
Dr. Petersen pioneered the characterization of MCI as a distinct clinical entity:
- Established diagnostic criteria for amnestic MCI
- Demonstrated that MCI represents a transitional stage between normal aging and dementia
- Documented the progression rates from MCI to Alzheimer's disease
Biomarker Research
His biomarker research has focused on:
- CSF biomarkers: Amyloid and tau measurements in cerebrospinal fluid
- Neuroimaging: PET and MRI markers of Alzheimer's pathology
- Clinical biomarkers: Cognitive tests and functional assessments
Clinical Trials
Dr. Petersen has been instrumental in:
- Designing clinical trials for Alzheimer's disease prevention
- Evaluating anti-amyloid and anti-tau therapies
- Developing outcome measures for clinical trials
Major Awards and Recognition
- Potamkin Prize for Alzheimer's Research
- Metropolitan Life Foundation Award
- Alzheimer's Association Lifetime Achievement Award
Key Publications
His work has resulted in over 500 peer-reviewed publications, including seminal papers on MCI diagnostic criteria and biomarker validation.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mild Cognitive Impairment](/diseases/mci)
- [Mayo Clinic](/institutions/mayo-clinic)
External Links
- [Mayo Clinic Profile](https://www.mayoclinic.org/doctors/ronald-petersen)
- [PubMed Publications](https://pubmed.ncbi.nlm.nih.gov/?term=Petersen+RC+Alzheimer)
Overview
Ronald C. Petersen plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Ronald C. Petersen has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Collaborations
Dr. Petersen has established numerous collaborative research networks:
- National Institute on Aging-funded Alzheimer's Disease Research Centers
- International Alzheimer's Disease Genetic Consortium
- Multi-site biomarker validation studies
These collaborations have enabled the largest-ever studies of preclinical and prodromal Alzheimer's disease, with data shared across hundreds of researchers worldwide.
His work continues to drive advances in understanding and treating these devastating diseases, with ongoing studies exploring novel therapeutic approaches and early intervention strategies. These efforts have significantly improved our ability to diagnose, monitor, and treat patients with neurodegenerative conditions.
Clinical Practice
In addition to his research contributions, Dr. Petersen maintains an active clinical practice seeing patients with memory disorders. He emphasizes the importance of early diagnosis and intervention, working with patients and families to develop comprehensive care plans that incorporate both pharmacological and lifestyle approaches to managing cognitive decline.
His clinical work has informed his research priorities, ensuring that scientific discoveries are translated into practical applications that benefit patients immediately.
Research Contributions
Mermaid diagram (expand to render)
Recent Publications (2024-2026)
- Journal Article. FDG-PET imaging to identify brain regions associated with Alzheimer's disease-related TDP-43 proteinopathy: A predictive model using penalized logistic regression analysis.. J Alzheimers Dis. 2026 Mar 13. PMID: 41823675(https://pubmed.ncbi.nlm.nih.gov/41823675/)
- Journal Article. A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.. Nat Genet. 2026 Mar 12. PMID: 41820575(https://pubmed.ncbi.nlm.nih.gov/41820575/)
- Journal Article. Tau PET overlap index correlation with neuropathological findings.. Alzheimers Dement. 2026 Mar. PMID: 41795671(https://pubmed.ncbi.nlm.nih.gov/41795671/)
- Journal Article. Hippocampal subfield thickness and shape analysis in examining the impact of TDP-43 in primary age-related tauopathy.. Alzheimers Dement. 2026 Mar. PMID: 41795660(https://pubmed.ncbi.nlm.nih.gov/41795660/)
- Journal Article. Plasma biomarkers of Alzheimer's disease and their association with disproportionately enlarged subarachnoid space hydrocephalus.. Fluids Barriers CNS. 2026 Mar 5. PMID: 41787435(https://pubmed.ncbi.nlm.nih.gov/41787435/)
References
[Petersen RC et al., Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999 (1999)](https://pubmed.ncbi.nlm.nih.gov/10190820/)
[Petersen RC et al., Amyloid imaging in cognitively normal individuals. Lancet Neurol 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25982310/)
[Petersen RC et al., Alzheimer's Disease Biomarkers. Nat Rev Neurol 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31118486/)